✦ LIBER ✦

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

✍ Scribed by Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso

Book ID: 117280899
Publisher: The Lancet
Year: 2002
Tongue: English
Weight: 469 KB
Volume: 359
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(02)08905-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acarbose for type 2 diabetes prevention

✍ André J Scheen 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 49 KB

Acarbose for type 2 diabetes prevention

✍ Ingrid Mühlhauser 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 50 KB

Acarbose for type 2 diabetes prevention

✍ J-L Chiasson 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 50 KB

Prevention of Type 2 Diabetes || Decreas

Prevention of Type 2 Diabetes || Decreasing Postprandial Plasma Glucose Using an α-Glucosidase Inhibitor in Subjects with IGT for the Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Trial

✍ LeRoith, Derek 📂 Article 📅 2012 🏛 Springer New York 🌐 English ⚖ 597 KB

There Is A World-wide Epidemic On Obesity. This Epidemic Is Driving The Immense Proportions Of Type 2 Diabetes Across The Globe. While There Are Numerous Therapies For Treating Type 2 Diabetes, The Most Effective Therapy Is Prevention. Prevention Of Type 2 Diabetes Can Be Achieved Properly By Simult

Acarbose for prevention of diabetes, hyp

Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data

✍ T. Kaiser; P. T. Sawicki 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 146 KB

Acarbose for the prevention of Type 2 di

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

✍ J.-L. Chiasson; R. G. Josse; R. Gomis; M. Hanefeld; A. Karasik; M. Laakso; the S 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 147 KB